EyeGene Inc.

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

N/A

Website

www.eyegene.co.kr

Country

South Korea

Exchange

KOSDAQ

Founded 2000Seoul, South Korea

EyeGene provides the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. Its product pipeline comprises EG-Mirotin, which has completed Phase 2a clinical trial to treat diabetic retinopathy.

Its portfolio also includes EG-Decorin which completed Phase 2 clinical trial for the treatment of pressure ulcers and wound healing, and EG-Myocin, which has completed Phase II clinical trials for the treatment of myocardial ischemia/reperfusion injury. It also develops EG-HZ, which has completed phase 1 clinical trial for the treatment of herpes zoster.

Its portfolio also includes EG-HPV which completed Phase 1 clinical trial to treat cervical cancer, EG-COVID that is in phase I clinical trial for the treatment of covid, and EG-TB for the tuberculosis vaccine and is in preclinical trial vitalDB for beautiful vitality. Founded in 2000, EyeGene is headquartered in Seoul, South Korea.

Key Stats

52-Week Range

₩1182.00₩3450.00

Beta0.56

Trailing P/EN/A

Forward P/EN/A

Trailing EPSN/A

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.